These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2697762)

  • 1. An analysis of clinical toxicology urine specimens using the KDI Quik test.
    Kaplan RM; Fochtman F; Brunett P; White C; Heller MB
    J Toxicol Clin Toxicol; 1989; 27(6):369-73. PubMed ID: 2697762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Keystone Diagnostics Quik Test using previously screened urine specimens.
    Bogema S; Schwartz R; Godwin I
    J Anal Toxicol; 1988; 12(5):272-3. PubMed ID: 3226124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Keystone Diagnostic Quik Test. A paper chromatography test for drugs of abuse in urine.
    Schwartz RH; Bogema S; Thorne MM
    Arch Pathol Lab Med; 1989 Apr; 113(4):363-4. PubMed ID: 2650652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cloned enzyme donor immunoassay (CEDIA) for drugs-of-abuse screening.
    Armbruster DA; Hubster EC; Kaufman MS; Ramon MK
    Clin Chem; 1995 Jan; 41(1):92-8. PubMed ID: 7813088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Triage screening for drugs of abuse in postmortem blood and urine samples.
    Moriya F; Hashimoto Y
    Nihon Hoigaku Zasshi; 1997 Jun; 51(3):214-9. PubMed ID: 9301227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of adulterating agents on FPIA analysis of urine for drugs of abuse.
    Schwarzhoff R; Cody JT
    J Anal Toxicol; 1993; 17(1):14-7. PubMed ID: 8429620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of validity of the KDI Quik Test Drug Screen for detection of benzoylecgonine in urine.
    Cone EJ; Menchen SL
    J Anal Toxicol; 1987; 11(6):276-7. PubMed ID: 3431098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance characteristics of DRI, CEDIA, and REMEDi systems for preliminary tests of amphetamines and opiates in human urine.
    Huang MK; Dai YS; Lee CH; Liu C; Tsay WI; Li JH
    J Anal Toxicol; 2006; 30(1):61-4. PubMed ID: 16620534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Microgenics CEDIA heroin metabolite (6-AM) and the Roche Abuscreen ONLINE opiate immunoassays for the detection of heroin use in forensic urine samples.
    Holler JM; Bosy TZ; Klette KL; Wiegand R; Jemionek J; Jacobs A
    J Anal Toxicol; 2004 Sep; 28(6):489-93. PubMed ID: 15516301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct ELISA kits as a sensitive and selective screening method for abstinence control in urine.
    Kirschbaum KM; Musshoff F; Wilbert A; Röhrich J; Madea B
    Forensic Sci Int; 2011 Apr; 207(1-3):66-9. PubMed ID: 20933345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Status of drugs-of-abuse testing in urine: An AACC study.
    Frings CS; White RM; Battaglia DJ
    Clin Chem; 1987 Sep; 33(9):1683-6. PubMed ID: 3621586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a new phencyclidine enzyme immunoassay for the detection of phencyclidine in urine with confirmation by high-performance liquid chromatography-tandem mass spectrometry.
    Poklis JL; Guckert B; Wolf CE; Poklis A
    J Anal Toxicol; 2011 Sep; 35(7):481-6. PubMed ID: 21871157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and evaluation of immunochromatographic rapid tests for screening of cannabinoids, cocaine, and opiates in urine.
    Wennig R; Moeller MR; Haguenoer JM; Marocchi A; Zoppi F; Smith BL; de la Torre R; Carstensen CA; Goerlach-Graw A; Schaeffler J; Leinberger R
    J Anal Toxicol; 1998; 22(2):148-55. PubMed ID: 9547412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analytic performance of immunoassays for drugs of abuse below established cutoff values.
    Luzzi VI; Saunders AN; Koenig JW; Turk J; Lo SF; Garg UC; Dietzen DJ
    Clin Chem; 2004 Apr; 50(4):717-22. PubMed ID: 14764642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. False-positive immunochemical screen for methadone attributable to metabolites of verapamil.
    Lichtenwalner MR; Mencken T; Tully R; Petosa M
    Clin Chem; 1998 May; 44(5):1039-41. PubMed ID: 9590378
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of three commercial tests for buprenorphine screening in urine.
    Leino A; Loo BM
    Ann Clin Biochem; 2007 Nov; 44(Pt 6):563-5. PubMed ID: 17961313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A field evaluation of five on-site drug-testing devices.
    Crouch DJ; Hersch RK; Cook RF; Frank JF; Walsh JM
    J Anal Toxicol; 2002 Oct; 26(7):493-9. PubMed ID: 12423006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a visual panel detection method for drugs of abuse: clinical and laboratory experience with children and adolescents.
    Valentine JL; Komoroski EM
    J Pediatr; 1995 Jan; 126(1):135-40. PubMed ID: 7815204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug screening in urine by cloned enzyme donor immunoassay (CEDIA) and kinetic interaction of microparticles in solution (KIMS): a comparative study.
    Schwettmann L; Külpmann WR; Vidal C
    Clin Chem Lab Med; 2006; 44(4):479-87. PubMed ID: 16599844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detecting cocaine and opiates in urine: comparing three commercial assays.
    Schilling RF; Bidassie B; El-Bassel N
    J Psychoactive Drugs; 1999; 31(3):305-13. PubMed ID: 10533978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.